APRE
Aprea Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Aprea Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
—
No changes.
No changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); Phase I clinical trials for the treatment of relapsed/refractory TP53 mutant chronic lymphoid leukemia; and Phase I/II clinical trials in relapsed/refractory gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator, which is in Phase I clinical trials for the treatment of MDS and AML. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); Phase I clinical trials for the treatment of relapsed/refractory TP53 mutant chronic lymphoid leukemia; and Phase I/II clinical trials in relapsed/refractory gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator, which is in Phase I clinical trials for the treatment of MDS and AML. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
No thesis.
Annual filing, covered
10-K parsed · Mar 16 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 16 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Aprea Therapeutics, Inc.
0.51
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Aprea Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Aprea Therapeutics, Inc..
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| AIGH | $814,768 | 40.49% | 0.00% |
| Vestal Point Capital | $280,805 | 13.96% | 0.00% |
| Sphera Funds | $216,621 | 10.77% | 0.00% |
| Nantahala | $165,081 | 8.20% | 0.00% |
| Stonepine | $110,000 | 5.47% | new |
| Manager | Value | % base | |
|---|---|---|---|
| AIGH | $814,768 | 40.49% | 0.00% |
| Vestal Point Capital | $280,805 | 13.96% | 0.00% |
| Sphera Funds | $216,621 | 10.77% | 0.00% |
| Nantahala | $165,081 | 8.20% | 0.00% |
| Stonepine | $110,000 | 5.47% | new |